RU93005089A - MANUFACTURING HUMAN PROTEIN, DNA, CELL, PHARMACEUTICAL COMPOSITION, USE OF DERIVATIVE PROTEIN C, METHOD OF OBTAINING - Google Patents

MANUFACTURING HUMAN PROTEIN, DNA, CELL, PHARMACEUTICAL COMPOSITION, USE OF DERIVATIVE PROTEIN C, METHOD OF OBTAINING

Info

Publication number
RU93005089A
RU93005089A RU93005089/13A RU93005089A RU93005089A RU 93005089 A RU93005089 A RU 93005089A RU 93005089/13 A RU93005089/13 A RU 93005089/13A RU 93005089 A RU93005089 A RU 93005089A RU 93005089 A RU93005089 A RU 93005089A
Authority
RU
Russia
Prior art keywords
protein
dna
obtaining
cell
pharmaceutical composition
Prior art date
Application number
RU93005089/13A
Other languages
Russian (ru)
Other versions
RU2122004C1 (en
Inventor
Эдвард Герлитз Брюс
Уильям Гриннелл Брайен
Original Assignee
Ели Лилли энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ели Лилли энд Компани filed Critical Ели Лилли энд Компани
Publication of RU93005089A publication Critical patent/RU93005089A/en
Application granted granted Critical
Publication of RU2122004C1 publication Critical patent/RU2122004C1/en

Links

Claims (1)

Изобретение относится к производным человеческого протеина С с высокой активностью и сниженной зависимостью от тромбиновой активации. Эти производные отличаются от природных форм человеческого протеина с повышенной степенью активации, функциональной активностью и углеводородными структурами. Приведены ДНК соединения, векторы переноса, векторы экспрессии и трансформанты, применимые для получения этих производных.The invention relates to derivatives of human protein C with high activity and reduced dependence on thrombin activation. These derivatives differ from the natural forms of human protein with a high degree of activation, functional activity and hydrocarbon structures. The DNA compounds, transfer vectors, expression vectors and transformants applicable to the preparation of these derivatives are shown.
RU93005089A 1992-05-21 1993-05-19 Derivative of human c-protein and a pharmaceutical composition showing antithrombic effect RU2122004C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21
US07/887,191 1992-05-21
US07/887.191 1992-05-21

Publications (2)

Publication Number Publication Date
RU93005089A true RU93005089A (en) 1996-03-10
RU2122004C1 RU2122004C1 (en) 1998-11-20

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93005089A RU2122004C1 (en) 1992-05-21 1993-05-19 Derivative of human c-protein and a pharmaceutical composition showing antithrombic effect

Country Status (23)

Country Link
US (1) US5453373A (en)
EP (1) EP0575054B1 (en)
JP (1) JP3564150B2 (en)
KR (1) KR100291529B1 (en)
CN (1) CN1080658A (en)
AT (1) ATE286121T1 (en)
AU (1) AU661901B2 (en)
BR (1) BR9301944A (en)
CA (1) CA2096604C (en)
CZ (1) CZ286016B6 (en)
DE (1) DE69333727T2 (en)
DK (1) DK0575054T3 (en)
ES (1) ES2233925T3 (en)
FI (1) FI932282A (en)
HU (1) HU218408B (en)
IL (1) IL105757A0 (en)
MX (1) MX9302917A (en)
MY (1) MY110664A (en)
NO (1) NO311299B1 (en)
NZ (1) NZ247651A (en)
PH (1) PH29911A (en)
PT (1) PT575054E (en)
RU (1) RU2122004C1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (en) * 1991-06-20 1997-03-25 Immuno Ag MEDICINAL ACTIVATED PROTEIN C
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
DE4320294A1 (en) * 1993-06-18 1994-12-22 Immuno Ag Use of human protein C to prevent and treat platelet deposits
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HU224826B1 (en) 1997-04-28 2006-02-28 Lilly Co Eli Activated protein c formulations
ZA984698B (en) * 1997-06-05 2000-02-01 Lilly Co Eli Methods for treating thombotic disorders.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JP2003506006A (en) * 1998-07-31 2003-02-18 イーライ・リリー・アンド・カンパニー Cold granulation of activated protein C
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CN1324244A (en) 1998-10-22 2001-11-28 伊莱利利公司 Methods for treating sepsis
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
ES2195655T3 (en) 1998-11-20 2003-12-01 Lilly Co Eli PROCEDURE TO TREAT VIRIC HEMORRAGICAL FEVER WITH PROTEIN C.
BR9915572A (en) 1998-11-23 2001-08-14 Lilly Co Eli Process of treatment of sickle cell disease and thalassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003514545A (en) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー Protein C derivative
ES2234807T3 (en) * 2000-02-02 2005-07-01 Eli Lilly And Company DERIVATIVES OF PROTEIN C.
EP1263943A1 (en) * 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
KR20030060915A (en) * 2000-10-18 2003-07-16 맥시겐 에이피에스 Protein c or activated portein c-like molecules
IL154999A0 (en) * 2000-10-18 2003-10-31 Maxygen Aps Protein c or activated protein c-like molecules
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
WO2003106666A2 (en) * 2002-06-14 2003-12-24 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
EP1913155A4 (en) * 2005-06-23 2009-08-12 Univ British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
EP2178556B1 (en) * 2007-06-18 2011-08-17 Oregon Health & Science University Protein c for use in maintaining hemostasis
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN104262479A (en) 2008-12-19 2015-01-07 国家健康与医学研究院 Serine Protease Derivatives And Uses In The Prevention Or The Treatment Of Blood Coagulation Disorders
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
DK3137102T3 (en) 2014-04-16 2021-10-11 Zz Biotech Llc APC FOR USE FOR THE TREATMENT OF ABNORMAL CUTANE FORMATION
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Similar Documents

Publication Publication Date Title
RU93005089A (en) MANUFACTURING HUMAN PROTEIN, DNA, CELL, PHARMACEUTICAL COMPOSITION, USE OF DERIVATIVE PROTEIN C, METHOD OF OBTAINING
NO890921D0 (en) PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES.
NO882732D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
FR2629825B1 (en) NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
ATA285187A (en) SUBSTITUTED ALPHA AMINO ACIDS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM
NO873699D0 (en) POLYPEPTIDE SUITABLE FOR DIMENSION, TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASES SUCH AS ARTICLES.
NO871295D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
IT8647666A0 (en) PEPTIDES AND PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
RU94041224A (en) PEPTIDES WITH ORGAN-PROTECTIVE ACTIVITY, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND THEIR USE IN THERAPY
CA2114313A1 (en) Bpc peptides, their preparation and use
FR2694296B1 (en) Peptides inhibiting the activity of ras proteins, preparation and use.
NO870049D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
NO165071C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 7- (3-AMINO-1-PYRROLIDINYL) -8-CHLORO-1-CYCLOPROPYL-6-FLUORO-1,4, -DIHYDRO-4-OXO-3-CHINOLINE-CARBOXYL.
NO166326C (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3,7-SUBSTITUTED-8-OXO-5-THIA-1-AZABICYCLO- (4,2,0) OCT-2-EN-2-CARBOXYLATER.
NO863373D0 (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
DE68917837D1 (en) Peptide compounds.
FI892684A (en) Process for the preparation of therapeutically active 4-oxoimidazo [1,5-a] quinoxaline derivatives
DE68907392T2 (en) Dysmnesia modifying drugs.
NO893794L (en) PROCEDURE FOR THE PREPARATION OF IMPROVED HYDROLYZEATED PROTEIN.
ATE90359T1 (en) PEPTIDES.
IT8819791A0 (en) PEPTIDES WITH PHARMACEUTICAL ACTIVITY.
EP0780472A3 (en) Stress proteins
NO166280C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE N, N'-DISUBSTITUTED UREA.
NO172491C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,3-DIOXANE-ALCOHIC ACID DERIVATIVES
FI894812A0 (en) Process for the preparation of pharmacologically valuable 2-carbonyl-substituted N, N'-di (trimethoxybenzoyl) piperazines